Fibromyalgia is not classified as an autoimmune disease. The American College of Rheumatology states plainly that fibromyalgia is “not an inflammatory or autoimmune disease” and that research points to the nervous system as the primary driver. But the picture is more complicated than a simple no, and recent discoveries are challenging the clean boundaries between autoimmune and neurological conditions.
Why Fibromyalgia Isn’t Considered Autoimmune
Autoimmune diseases share a defining feature: the immune system attacks the body’s own tissues, causing measurable inflammation and damage. In rheumatoid arthritis, for example, immune cells destroy joint lining. In lupus, antibodies target organs throughout the body. Blood tests in these conditions reveal specific autoantibodies and high levels of inflammatory markers that confirm the immune system is misfiring.
Fibromyalgia doesn’t follow this pattern. There’s no tissue destruction, no telltale autoantibodies on standard blood panels, and no consistent elevation in the classic markers of systemic inflammation. Some inflammatory signaling molecules do show unusual levels in fibromyalgia patients. One study found that a key inflammation-related protein (IL-6) was roughly 17 times higher in fibromyalgia patients than in healthy volunteers. But other inflammatory markers were actually lower or undetectable. This mixed, inconsistent inflammatory profile doesn’t match the signature of autoimmune disease.
What’s Actually Happening in the Nervous System
The current understanding centers on something called central sensitization: the brain and spinal cord become hypersensitive to pain signals, essentially turning up the volume on sensations that wouldn’t normally register as painful. This involves changes in how neurotransmitters are released and how nerve signals are processed, making the nervous system overreact to pressure, temperature, and other stimuli.
But sensitization isn’t limited to the brain. Peripheral nerves, the ones running through your skin and muscles, are also affected. About 50% of women with fibromyalgia show reduced nerve fiber density in their skin when examined under a microscope. One study found that 63% of fibromyalgia patients had measurably fewer nerve fibers in skin biopsies, compared to 18% of healthy controls. This loss of small nerve fibers, a condition called small fiber neuropathy, helps explain why fibromyalgia patients experience heightened pain sensitivity and unusual sensations like tingling or burning.
Researchers now describe fibromyalgia as involving central, peripheral, and psychosocial sensitization all at once. It’s not a single broken switch but a cascade of changes across the entire pain-processing system.
The Antibody Study That Complicated Things
A 2021 study published in The Journal of Clinical Investigation shook the debate. Researchers purified antibodies (IgG) from the blood of fibromyalgia patients and injected them into healthy mice. The results were striking: mice that received fibromyalgia patients’ antibodies developed heightened sensitivity to painful pressure and cold, reduced grip strength, and decreased physical activity. Mice that received antibodies from healthy people showed none of these changes. When researchers used blood from the same fibromyalgia patients but removed the antibodies first, the effects also disappeared.
The antibodies appeared to work by binding directly to pain-sensing nerve cells and their surrounding support cells in sensory nerve clusters. All eight individual patients’ antibodies produced mechanical hypersensitivity in mice, and seven of eight also produced cold sensitivity. The researchers concluded that “therapies reducing patient IgG titers may be effective for fibromyalgia.”
This is significant because passive transfer of symptoms through antibodies is a hallmark of autoimmune disease. If antibodies alone can recreate the condition, it suggests the immune system plays a more central role than previously thought. However, one study doesn’t rewrite a diagnosis. The targets these antibodies bind to haven’t been fully identified, and it’s unclear whether the antibody activity represents a primary cause or a secondary effect of another process.
How Fibromyalgia Overlaps With Autoimmune Conditions
Fibromyalgia frequently coexists with genuine autoimmune diseases, which adds to the confusion. A large meta-analysis found that 21% of people with rheumatoid arthritis also meet the criteria for fibromyalgia. The overlap is similarly high in other inflammatory conditions: 18% in psoriatic arthritis and 13% in ankylosing spondylitis. This means roughly one in five people with inflammatory arthritis also has fibromyalgia layered on top.
This overlap creates a real clinical problem. Fibromyalgia pain doesn’t respond to the immune-suppressing drugs that treat autoimmune conditions. If a rheumatoid arthritis patient also has unrecognized fibromyalgia, their doctor might keep escalating immune therapy for pain that has a completely different source. Understanding that fibromyalgia is a separate process, even when it appears alongside autoimmune disease, changes how it needs to be managed.
How Fibromyalgia Is Diagnosed
There’s no blood test or imaging scan that confirms fibromyalgia. Diagnosis relies on two scoring tools developed by the American College of Rheumatology. The Widespread Pain Index maps 19 areas of the body and counts how many are painful. The Symptom Severity Scale rates the intensity of fatigue, unrefreshing sleep, and cognitive symptoms (often called “fibro fog”) on a 0 to 3 scale. Meeting specific thresholds on both scales, after other conditions have been ruled out, leads to a diagnosis.
This means diagnosis is partly about exclusion. Your doctor will typically run blood work to check for autoimmune markers, thyroid problems, and other conditions that mimic fibromyalgia symptoms. Normal results on those tests, combined with the characteristic pattern of widespread pain and accompanying symptoms, point toward fibromyalgia.
What This Means for Treatment
Because fibromyalgia operates through the nervous system rather than the immune system, treatment looks different from autoimmune disease management. Anti-inflammatory drugs and immune-suppressing medications generally don’t help. Instead, the most effective approaches target nerve signaling and pain processing: medications that calm overactive nerve transmission, physical activity that gradually retrains the pain system, cognitive behavioral therapy, and sleep improvement strategies.
The antibody research could eventually change this. If future studies confirm that immune molecules drive a meaningful portion of fibromyalgia symptoms, treatments that filter or reduce antibodies might become an option. For now, though, the practical reality is that fibromyalgia responds best to a multidisciplinary approach focused on the nervous system, not the immune system.